Setting a new standard in immunotherapy
monitoring
Dr. Lisa Russelli is a nuclear medicine specialist and visionary entrepreneur dedicated to advancing cancer diagnostics. With a robust background in radiopharmaceutical research and a passion for inclusive innovation, she co-leads imuveo in developing cutting-edge PET tracers to enhance immunotherapy outcomes. Her commitment to scientific excellence and diversity drives the company's mission to transform patient care.
Lisa earned her PhD in Nuclear Medicine from the Technical University of Munich, focusing on developing innovative chelators for PET tracers using isotopes like Zr-89 and AlF-18. Her work enhances precision in immunoPET imaging.
As Co-CEO of imuveo, Lisa leads the scientific development of PET-based imaging tools aimed at improving cancer immunotherapy monitoring. Her leadership has been pivotal in securing funding and driving the company's mission forward.
Originally from Italy, Lisa brings a unique cultural viewpoint to the team, enriching imuveo's approach to innovation and collaboration.
Lisa is committed to fostering equality and diversity within the startup ecosystem, actively participating in initiatives that support female founders and underrepresented groups in science and entrepreneurship.
Paul Klein is a strategic thinker and builder at the intersection of data science, economics, and healthcare innovation. With a rich background in business analytics, public management, and machine learning, he co-leads imuveo’s operational strategy and growth. His mission: to create a lasting platform for next-generation imaging and radioligand therapies that transform patient care.
Paul holds dual master’s degrees in Data Science & Intelligent Analytics and Economics with a focus on Public Management - a rare blend that drives both strategic and analytical strength at imuveo.
With nearly a decade of experience in business analysis, IT consulting, and public sector innovation, Paul brings a structured, impact-driven approach to scaling biotech operations.
From Machine Learning Engineering to business analytics for mobility and public projects, Paul combines deep data skills with real-world operational leadership.
As Co-Founder and COO of imuveo, Paul is not just building today’s operations but setting the foundations for a sustainable, innovative pipeline in diagnostics and future therapies.
Dr. Dario Gosmann is a published immunologist and translational scientist dedicated to revolutionizing cancer care. His research at TUM focused on T-cell-based diagnostics and immune monitoring, and he has authored multiple papers in the field. As Co-Founder and Co-CEO of imuveo, he leads scientific strategy and pipeline development - turning deep research insights into real-world tools that enhance how cancer is diagnosed, monitored, and treated.
Dario completed his PhD at the Technical University of Munich, focusing on immune monitoring and T-cell engineering - core areas for next-gen cancer immunotherapy.
His work has been published in high-impact journals and covers T-cell profiling, biomarker discovery, and the development of immune-based diagnostics — providing a strong foundation for imuveo's science-driven platform.
Backed by the prestigious EXIST Transfer of Research program, Dario co-founded imuveo to bring immune imaging tools from lab to clinic — starting with PET tracers and aiming for radioligand therapies.
With experience at leading institutions across Germany and the Netherlands, Dario combines scientific depth with a clear goal: smarter, faster treatment decisions for patients through advanced imaging and therapy.
Bridging Innovation and Execution -
Meet Our Advisors.
Prof. Dr. Weber
Head of Nuclear Medicine department (TUM, Munich)
Prof. Dr. Krackhardt
Chief Physician in Oncology (St. Franziskus-Hospital, Flensburg)
Dr. D‘Alessandria
Head of Radiopharmacy (TUM, Munich)
Dr. Annette Veltmar, PhD, MBA
Drove market access and launches
Transformed R&D into commerce
Dr. Anne Margo Reintsema, MD MBA
Advisor and investor driving innovation
Expert in strategy and M&A
From bench to bedside -
Step by step
-
In vitro analyses
It works in the lab
-
In vivo safetyIt’s safe in animal models and for human T cells
-
In vivo feasibility:
It clearly visualizes T cells in animals and distinguishes responders from nonn-responders
-
GMPProduction Process Set
-
RadioGMP
The tracer is clinical-grade ready
-
Clinical documents ready
Protocos for Phase I in place
-
CRO Onboard
Trial Partner & clinical champions secured
-
Approval In SightPhase I Plan Accepted
Unlock the power of T-cell imaging - whether you're investing or innovating.
Shape the future of immunotherapy - join us in setting a new standard and backing our Phase 1 trial, as partner or investor.
-
The ecosystem is established and key players see the potential.
-
Every step along the way adds value to our project – and increases your ROI.
-
Boost your preclinical pipeline -add value to your biotech or pharma projects with precise T-cell tracking.